Vanguard Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-7,154,343
| Closed | -$293M | – | 4433 |
|
|
2024
Q2 | $293M | Sell |
7,154,343
-309,568
| -4% | -$12.7M | 0.01% | 1276 |
|
|
2024
Q1 | $315M | Buy |
7,463,911
+88,941
| +1% | +$3.76M | 0.01% | 1261 |
|
|
2023
Q4 | $313M | Buy |
7,374,970
+1,003,594
| +16% | +$42.6M | 0.01% | 1259 |
|
|
2023
Q3 | $139M | Buy |
6,371,376
+708,826
| +13% | +$15.5M | ﹤0.01% | 1631 |
|
|
2023
Q2 | $180M | Sell |
5,662,550
-464,030
| -8% | -$14.8M | ﹤0.01% | 1517 |
|
|
2023
Q1 | $149M | Buy |
6,126,580
+88,119
| +1% | +$2.15M | ﹤0.01% | 1609 |
|
|
2022
Q4 | $190M | Buy |
6,038,461
+164,460
| +3% | +$5.19M | 0.01% | 1463 |
|
|
2022
Q3 | $166M | Buy |
5,874,001
+861,581
| +17% | +$24.3M | ﹤0.01% | 1500 |
|
|
2022
Q2 | $133M | Buy |
5,012,420
+202,727
| +4% | +$5.36M | ﹤0.01% | 1653 |
|
|
2022
Q1 | $168M | Buy |
4,809,693
+7,856
| +0.2% | +$275K | ﹤0.01% | 1652 |
|
|
2021
Q4 | $156M | Buy |
4,801,837
+108,678
| +2% | +$3.52M | ﹤0.01% | 1744 |
|
|
2021
Q3 | $138M | Buy |
4,693,159
+1,168,443
| +33% | +$34.5M | ﹤0.01% | 1800 |
|
|
2021
Q2 | $90.3M | Buy |
3,524,716
+296,575
| +9% | +$7.6M | ﹤0.01% | 2045 |
|
|
2021
Q1 | $44.3M | Buy |
3,228,141
+82,067
| +3% | +$1.13M | ﹤0.01% | 2384 |
|
|
2020
Q4 | $52.2M | Buy |
+3,146,074
| New | +$52.2M | ﹤0.01% | 2178 |
|